Educational Guide
NAD+ Delivery Methods: IV, IM, Subcutaneous, Oral Precursors, and NADH
A practical guide comparing common NAD+-related delivery approaches, including IV NAD+, intramuscular injections, subcutaneous injections, oral NR and NMN, and oral NADH. It explains differences in onset, tolerability, supervision needs, absorption, reported dose ranges, and the distinction between direct NAD+ administration and precursor-based NAD+ support.
Why NAD+ delivery method matters
Nicotinamide adenine dinucleotide, or NAD+, is a core cellular coenzyme rather than a peptide. It participates in energy metabolism by cycling between NAD+ and NADH, helping cells move electrons through glycolysis, the Krebs cycle, and oxidative phosphorylation to support ATP production.
NAD+ is also used by enzyme systems involved in DNA repair, mitochondrial regulation, immune signaling, inflammation-related pathways, and circadian rhythm control. Sirtuins, PARP enzymes, CD38, and circadian enzymes are all connected to NAD+ availability or turnover.
Delivery method matters because direct NAD+ administration, NAD+ precursors, and NADH are not interchangeable. IV, intramuscular, and subcutaneous approaches administer NAD+ directly. Oral NR and NMN are precursors intended to raise NAD+ through salvage pathways. NADH is the reduced form of NAD+ and is discussed separately from NAD+ precursor supplementation.
Direct NAD+ administration: IV, IM, and subcutaneous routes
Intravenous NAD+ delivers NAD+ directly into the bloodstream and is described as having full bioavailability by route of administration. It can accommodate larger clinic-based sessions, commonly described in the 500–1,000 mg range or higher over 1–4 hours.
The practical trade-off is that IV NAD+ requires time, cost, and medical supervision. Infusion rate is important: rapid administration has been associated with flushing, nausea, chest tightness, tachycardia, or general discomfort, so IV NAD+ is typically infused slowly.
Intramuscular, or IM, NAD+ is injected into muscle tissue. Because muscle is relatively vascular, IM administration is described as having a faster systemic onset than subcutaneous administration. It may be used in outpatient settings, but it can cause more injection-site soreness than subcutaneous delivery.
Reported IM protocol ranges include 50–100 mg for first-time tolerance testing, 100–250 mg one to three times weekly for general wellness use, and 500 mg or more one to two times weekly in higher-use protocols. These are reported ranges, not dosing recommendations.
Subcutaneous NAD+ and oral NAD+-related options
Subcutaneous, or SubQ, NAD+ is injected beneath the skin. Compared with IM delivery, it is described as slower and more time-released, with a delayed onset. It is also described as easier to administer and typically better tolerated, with a lower side-effect burden than faster or larger injections.
Reported SubQ protocol ranges include 25–50 mg for beginner use, 50–100 mg two to four times weekly for general wellness use, and 100–200 mg two to three times weekly in recovery or performance-oriented protocols. These ranges should be understood as contextual examples rather than instructions.
Oral NAD+ itself is described as poorly absorbed. Nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN, are oral NAD+ precursors that can support NAD+ production through salvage pathways. Multiple human trials are described as showing that daily NR or NMN can raise blood NAD+ levels by roughly 40–100%, although increased NAD+ levels do not necessarily translate into consistent clinical outcomes.
Reported oral ranges include 250–1,000 mg per day for NMN and 300–1,000 mg per day for NR, often taken in the morning in described protocols. Higher NR trial doses of 1,000–2,000 mg per day have been reported as well tolerated in some studies. These figures are not individualized guidance.
NADH as a related but distinct option
NADH is the reduced form of NAD+. Rather than serving as a precursor in the same way as NR or NMN, it participates directly in electron transfer before being converted back to NAD+ as electrons are donated into mitochondrial energy pathways.
Oral NADH has been discussed in relation to fatigue and cognitive fatigue. A chronic fatigue study cited in the material reported that 10 mg per day of oral NADH led to significant improvement in 31% of patients compared with 8% receiving placebo over four weeks. This finding is specific to that study context and should not be generalized beyond its design.
Reported NADH protocol ranges include 5–20 mg per day, commonly described as morning use. As with NAD+ and precursor approaches, these ranges should not be treated as personal dosing advice.
Comparing delivery routes in practical terms
| Approach | What is delivered | Absorption or onset profile | Supervision and tolerability considerations | Reported range examples |
|---|---|---|---|---|
| IV NAD+ | Direct NAD+ | Direct bloodstream delivery; used for larger, clinic-based sessions | Requires medical supervision; rapid infusion may cause flushing, nausea, chest tightness, tachycardia, or discomfort | 500–1,000 mg or more over 1–4 hours |
| IM NAD+ | Direct NAD+ | Faster systemic onset than subcutaneous delivery because muscle tissue is vascular | May be practical in outpatient use; may cause more soreness than SubQ | 50–100 mg tolerance test; 100–250 mg one to three times weekly; 500 mg or more in higher-use protocols |
| Subcutaneous NAD+ | Direct NAD+ | Slower, more time-released absorption with delayed onset | Often described as easier to administer and generally better tolerated than faster routes | 25–50 mg beginner range; 50–100 mg two to four times weekly; 100–200 mg two to three times weekly |
| Oral NR or NMN | NAD+ precursors | Raises NAD+ through salvage pathways; oral NAD+ itself is described as poorly absorbed | Non-injectable route; clinical effects may not match NAD+ elevation | NMN 250–1,000 mg per day; NR 300–1,000 mg per day; higher NR trial doses of 1,000–2,000 mg per day reported as tolerated in some studies |
| Oral NADH | Reduced form of NAD+ | Related to NAD+/NADH cycling rather than direct NAD+ precursor support | Discussed in fatigue-related contexts; evidence should be interpreted within study limits | 5–20 mg per day; one chronic fatigue study used 10 mg per day |
Evidence signals and limitations
The strongest biological rationale for NAD+ support is mechanistic: NAD+ is central to electron transfer, mitochondrial ATP generation, sirtuin activity, PARP-mediated DNA repair, immune signaling, and metabolic rhythm pathways. Evidence that NR and NMN can raise blood NAD+ is described as relatively consistent across multiple human trials.
Clinical outcomes are less certain. Reported findings include improved oxygen uptake and threshold power in runners after NMN supplementation, a chronic fatigue study in which oral NADH outperformed placebo over four weeks, and an IV NAD+ trial in healthy adults aged 30–55 using 750 mg per day for five days that reported improvement in six of eight cognitive tests with no adverse events.
Important gaps remain. Raising NAD+ does not guarantee improved insulin sensitivity, glucose metabolism, blood pressure, or muscle mitochondrial function. Direct NAD+ cellular uptake is complex, and a temporary IV increase may not equal sustained intracellular NAD+. Longer-term and higher-dose protocols require more human data.
Safety, cautions, and monitoring considerations
Commonly described side effects include flushing, nausea, headache, fatigue or drowsiness after injection, lightheadedness, injection-site discomfort, and chest tightness if NAD+ is pushed too quickly. Many tolerability issues are described as dose-rate related, especially with IV administration or larger IM injections.
Extra caution is described for people with low blood pressure, active or recent cancer, pregnancy or breastfeeding, severe kidney or liver disease, complex medication regimens, known methylation issues, severe anxiety or panic sensitivity, or unstable cardiovascular disease. Medication interactions and low blood pressure are specifically important considerations for clinician review.
Tracking in higher-use or longer-duration contexts may include subjective measures such as morning energy, afternoon fatigue, mental clarity, training recovery, sleep quality, exercise tolerance, and mood. Objective measures discussed include fasting glucose, fasting insulin, HbA1c, lipid panel, hs-CRP, ALT/AST, creatinine/eGFR, HRV, resting heart rate, VO2 max or endurance metrics, and, for higher-dose or longer cycles, homocysteine, B12, folate, methylmalonic acid, and RBC magnesium.
